Shyam A Patel,Abhishek A Mangaonkar
Shyam A Patel
Modern knowledge about the principles of clonal hematopoiesis of indeterminate potential (CHIP) has paved way for numerous clinical efforts aimed at managing this pre-malignant condition. The emergence of various CHIP clinics across the glo...
Benoît Gendrot,Carole Peyssonnaux,Isabelle Plo et al.
Benoît Gendrot et al.
Erythropoiesis and iron metabolism are closely interconnected, under both physiological and pathological conditions. Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN) caused by a Janus kinase-2 (JAK2) mutation, resulting in unco...
The clinical relevance of sole loss of chromosome Y in myeloid neoplasms [0.03%]
克隆型白血病Y染色体丢失的临床意义研究
Sandra Huber,Stephan Hutter,Manja Meggendorfer et al.
Sandra Huber et al.
Impact of thrombosis on disease progression, cancer and mortality in patients with essential thrombocythemia and polycythemia vera [0.03%]
血栓对原发性血小板增多症和真性红细胞增多症患者疾病进展、癌症及死亡率的影响
A Angona,B Cuevas,M Pérez-Encinas et al.
A Angona et al.
Dickran Kazandjian,Christin DeStefano,Sarah Darmon et al.
Dickran Kazandjian et al.
Monoclonal gammopathy of undetermined significance (MGUS) is a precursor condition for multiple myeloma, and although environmental exposures have been implicated in its pathogenesis, it is unknown whether exposure to open-air burn pits use...
Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigations [0.03%]
一种新型泛突变型BTK抑制剂-docirabrutinib在临床前和早期临床研究中通过抑制慢性淋巴细胞白血病中的B细胞受体信号通路发挥作用
Natalia Timofeeva,Breana Herrera,Hitomi Fujiwara et al.
Natalia Timofeeva et al.
BTK inhibitors (BTKi) have become standard of care for treatment of patients with chronic lymphocytic leukemia (CLL). Covalent BTKi (cBTKi) such as ibrutinib, acalabrutinib, and zanubrutinib are effective but alterations in the kinase domai...
A phase II study of daratumumab and ibrutinib for relapsed/refractory chronic lymphocytic leukemia [0.03%]
达拉莫苏单抗与伊布替尼联合治疗复发/难治慢性淋巴细胞白血病的II期研究
Ricardo D Parrondo,Sikander Ailawadhi,Betsy R Knopf et al.
Ricardo D Parrondo et al.
Real-world effectiveness and safety of blinatumomab in adults with B-cell precursor acute lymphoblastic leukaemia across 13 European countries [0.03%]
布林沙珠单抗治疗欧洲13个国家成人B细胞急性淋巴细胞白血病患者疗效和安全性的现实世界研究
Sabina Chiaretti,Sabine Blum,Thibaut Leguay et al.
Sabina Chiaretti et al.
A differentiated effector T cell repertoire defines a functionally high-risk group of smoldering myeloma patients [0.03%]
分化效应T细胞谱系定义了冒烟型多发性骨髓瘤的功能高危患者群
Ross S Firestone,Anish K Simhal,Theresia Akhlaghi et al.
Ross S Firestone et al.
Peripheral blood cfDNA detection using clonoSEQ assay in multiple myeloma is concordant with bone marrow and clinical biomarkers [0.03%]
用于多发性骨髓瘤的clonoseq检测外周血cfDNA与骨髓和临床生物标志物的一致性
J E Wiedmeier-Nutor,H E Kosiorek,M Arribas et al.
J E Wiedmeier-Nutor et al.